Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14
NCT ID: NCT00000262
Last Updated: 2015-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
1996-11-30
1999-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11
NCT00000259
Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13
NCT00000261
Effects of Subanesthetic Concentrations of Isoflurane/Nitrous Oxide - 3
NCT00000251
Isoflurane at Subanesthetic Concentrations - 6
NCT00000254
Minimum Alveolar Concentration of Sevoflurane With Nitrous Oxide Inducing Isoelectric EEG
NCT01705743
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo +/- 30% Nitrous oxide
30% Nitrous oxide
Placebo
Sevoflurane 0.2% +/- 30% Nitrous oxide
30% Nitrous oxide
0.2% sevoflurane
Sevoflurane 0.4% +/- 30% Nitrous oxide
30% Nitrous oxide
0.4% Sevoflurane
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
30% Nitrous oxide
0.4% Sevoflurane
0.2% sevoflurane
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
University of Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James Zacny, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Chicago
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Chicago, Anesthesia & Critical Care
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R01-08391-14
Identifier Type: -
Identifier Source: secondary_id
NIDA-08391-14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.